Report Overview

The stakes are high in the global oncology market, currently estimated at US$42 billion. Hundreds of novel and next-generation anticancer products are in research and development; however, not all are destined for market success and an estimated 37% or more key preclinical candidates may fail due to poor clinical performance despite increasing investment. The challenges for cancer research and drug development are many, but a number of strategies are proving advantageous in respect to the development of some promising oncology therapeutics.

Spectra's Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success is a unique and unrivalled 367-page report analysing the performance of numerous important early stage oncology drug candidates, assessing their market viability based on preclinical scientific studies and expert opinion. In the report, analysts decode the necessary parameters of market success for novel and next-generation drug targets. Through their diligent market research and academic insight, founded on years of experience of directing a preclinical research facility for the assessment of drug targets for solid tumours, the authors identify which oncology classes and products are most suited for regulatory approval and commercial success from those that may not fare as well in the global marketplace. The report represents an essential intelligence tool for deciphering capital risk and investment in oncology therapeutics whilst also enabling important decision-making with regard to research and development programmes and strategies, regulatory issues, and marketing challenges. Furthermore, market estimations for drug classes are provided revealing those preclinical and clinical phase compounds that are most likely to succeed in the market and become high-revenue therapeutics for their developers.